| pubmed-article:11834533 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11834533 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:11834533 | lifeskim:mentions | umls-concept:C0242339 | lld:lifeskim |
| pubmed-article:11834533 | lifeskim:mentions | umls-concept:C0286651 | lld:lifeskim |
| pubmed-article:11834533 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:11834533 | lifeskim:mentions | umls-concept:C2256728 | lld:lifeskim |
| pubmed-article:11834533 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11834533 | pubmed:dateCreated | 2002-2-8 | lld:pubmed |
| pubmed-article:11834533 | pubmed:abstractText | Human plasma platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A(2) that is primarily associated with low density lipoprotein (LDL). PAF-AH activity has also been found in high density lipoprotein (HDL), although it has recently been indicated that there is no PAF-AH protein in HDL. Plasma paraoxonase 1 (PON1) is an HDL-associated esterase, which also exhibits PAF-AH-like activity. The effect of atorvastatin (20 mg per day for 4 months) on PAF-AH and PON1 activities in patients with dyslipidemia of type IIA (n=55) or type IIB (n=21) was studied. In both patient groups, atorvastatin significantly reduced plasma PAF-AH activity because of the decrease in LDL plasma levels and the preferential decrease in PAF-AH activity on dense LDL subfractions (LDL-4 and LDL-5). Drug therapy did not affect HDL-associated PAF-AH activity or serum PON1 activities toward paraoxon and phenylacetate in either patient group. However, because of the reduction in LDL cholesterol levels, the ratios of HDL-associated PAF-AH and serum PON1 activities to LDL cholesterol levels were significantly increased after drug administration. The reduction of the LDL-associated PAF-AH activity and the elevation in the ratios of HDL-associated PAF-AH and PON1 activities to LDL plasma levels may represent a new dimension in the antiatherogenic effect of atorvastatin. | lld:pubmed |
| pubmed-article:11834533 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11834533 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11834533 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11834533 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11834533 | pubmed:issn | 1524-4636 | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:ElisafMosesM | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:TsimihodimosV... | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:KarabinaSonia... | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:TambakiAfrodi... | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:BairaktariEle... | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:GoudevenosJoh... | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:ChapmanM... | lld:pubmed |
| pubmed-article:11834533 | pubmed:author | pubmed-author:TselepisAlexa... | lld:pubmed |
| pubmed-article:11834533 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:11834533 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11834533 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:11834533 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11834533 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11834533 | pubmed:pagination | 306-11 | lld:pubmed |
| pubmed-article:11834533 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:meshHeading | pubmed-meshheading:11834533... | lld:pubmed |
| pubmed-article:11834533 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11834533 | pubmed:articleTitle | Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. | lld:pubmed |
| pubmed-article:11834533 | pubmed:affiliation | Department of Internal Medicine, University of Ioannina, Ioannina, Greece. | lld:pubmed |
| pubmed-article:11834533 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11834533 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11834533 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:11834533 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11834533 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11834533 | lld:pubmed |
